



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	10/717,101
		Filing Date	November 19, 2003
		First Named Inventor	Harold L. Atkins
		Art Unit	1648
		Examiner Name	Bao Q. Li
		Attorney Docket Number	18013-C1
Sheet		of	

[illegible][illegible]

Examiner Signature	BLI	Date Considered	09/23/2005
-----------------------	-----	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (07-05)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/717,101
		Filing Date	July 29, 2005
		First Named Inventor	Harold L. Atkins
		Art Unit	1648
		Examiner Name	Bao Q. Li
Sheet 1	of 1	Attorney Docket Number	18013-C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BCi		Stojdl, et al., "VSV Strains with Defect in their Ability to Shutdown Innate Immunity are Potent Systemic Anti-Cancer Agents", Cancer Cell, (2003) Vol. 4, pages 263-275.	
		Fernandez, et al., "Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease", Journal of Virology, (2002), Vol. 76, No. 2, pages 295-904.	
		Ebert, et al., "Oncolytic Vesicular Stomatitis Virus for Treatment of Orthotopic Hepatocellular Carcinoma in Immune-Competent Rats", Cancer Research, (2003), Vol. 63, pages 3605-3611.	
		Ebert, et al., "Systemic Therapy of Experimental Breast Cancer Metastases by Mutant Vesicular Stomatitis Virus in Immune-Competent Mice, Cancer Gene Therapy", (2005), Vol. 12, pages 350-358.	
		Porosnicu, et al., "The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene", Cancer Research, (2003), Vol. 63, pages 8366-8376.	
		Ahmed, et al., "Sensitivity of Prostate Tumors to Wild Type and M Protein Mutant Vesicular Stomatitis Viruses", Virology, (2004), Vol. 330, pages 34-49.	
		Balachandran, et al., "Oncolytic Activity of Vesicular Stomatitis Virus is Effective Against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of Apoptosis", Journal of Virology, (2001), Vol. 75, No. 7, pages 3474-3479.	

Examiner Signature	Bao Q. Li	Date Considered	
--------------------	-----------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.